Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Myc inhibition tips the immune balance to promote antitumor immunity

Cellular & Molecular Immunology volume 19, pages 1030–1041 (2022)Cite this article

Subjects

Abstract

Aberrant expression of Myc is one of the most common oncogenic events in human cancers. Scores of Myc inhibitors are currently under development for treating Myc-driven cancers. In addition to directly targeting tumor cells, Myc inhibition has been shown to modulate the tumor microenvironment to promote tumor regression. However, the effect of Myc inhibition on immune cells in the tumor microenvironment remains poorly understood. Here, we show that the adaptive immune system plays a vital role in the antitumor effect of pharmacologic inhibition of Myc. Combining genetic and pharmacologic approaches, we found that Myc inhibition enhanced CD8 T cell function by suppressing the homeostasis of regulatory T (Treg) cells and the differentiation of resting Treg (rTreg) cells to activated Treg (aTreg) cells in tumors. Importantly, we demonstrated that different Myc expression levels confer differential sensitivity of T cell subsets to pharmacologic inhibition of Myc. Although ablation of the Myc gene has been shown to suppress CD8 T cell function, Treg cells, which express much less Myc protein than CD8 T cells, are more sensitive to Myc inhibitors. The differential sensitivity of CD8 T and Treg cells to Myc inhibitors resulted in enhanced CD8 T cell function upon Myc inhibition. Our findings revealed that Myc inhibitors can induce an antitumor immune response during tumor progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding authors upon request.

References

  1. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

    Article  CAS  Google Scholar 

  2. Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–64.

    Article  CAS  Google Scholar 

  3. Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada J, et al. Deregulation of C-Myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science. 1986;232:884–6.

    Article  CAS  Google Scholar 

  4. Pelicci PG, Knowles DM, Favera RD. Lymphoid tumors displaying rearrangements of both immunoglobulin and T-cell receptor genes. J Exp Med. 1985;162:1015–24.

    Article  CAS  Google Scholar 

  5. Karim RZ, Tse GMK, Putti TC, Scolyer RA, Soon Lee C. The significance of the Wnt pathway in the pathology of human cancers. Pathology. 2004;36:120–8.

    Article  CAS  Google Scholar 

  6. Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer. 2015;15:593–607.

    Article  CAS  Google Scholar 

  7. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation (vol 18, pg 485, 2010). Cancer Cell. 2010;18:696.

    Article  CAS  Google Scholar 

  8. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–31.

    Article  CAS  Google Scholar 

  9. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–99.

    Article  CAS  Google Scholar 

  10. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.

    Article  CAS  Google Scholar 

  11. Freeman GJ，Long AJ，Iwai Y，Bourque K，Chernova T, Nishimura H. Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation. Blood. 2000;96:810a–1a.

    Google Scholar 

  12. Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171:1301–15.

    Article  CAS  Google Scholar 

  13. Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol. 2017;5:5943.

    Article  Google Scholar 

  14. Whitfield JR, Soucek L. The long journey to bring a Myc inhibitor to the clinic. J Cell Biol. 2021;220:e202103090.

    Article  CAS  Google Scholar 

  15. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]-pyrimidine. Chemmedchem. 2007;2:627–30.

    Article  CAS  Google Scholar 

  16. Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol. 2006;13:745–51.

    Article  CAS  Google Scholar 

  17. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35:871–82.

    Article  CAS  Google Scholar 

  18. Zemmour D, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat Immunol. 2018;19:291–301.

    Article  CAS  Google Scholar 

  19. Calado DP, Sasaki Y, Godinho SA, Pellerin A, Köchert K, Sleckman BP, et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol. 2012;13:1092–100.

    Article  CAS  Google Scholar 

  20. Dominguez-Sola D, Victora GD, Ying CY, Phan RT, Saito M, Nussenzweig MC, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol. 2012;13:1083–91.

    Article  CAS  Google Scholar 

  21. Huang CY, Bredemeyer AL, Walker LM, Bassing CH, Sleckman BP. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol. 2008;38:342–9.

    Article  CAS  Google Scholar 

  22. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001;14:45–55.

    Article  Google Scholar 

  23. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28:546–58.

    Article  CAS  Google Scholar 

  24. Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32:381–6.

    Article  CAS  Google Scholar 

  25. Feng Y, van der Veeken J, Shugay M, Putintseva EV, Osmanbeyoglu HU, Dikiy S, et al. A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature. 2015;528:132–6.

    Article  CAS  Google Scholar 

  26. Yang BH, Wang K, Wan S, Liang Y, Yuan X, Dong Y, et al. TCF1 and LEF1 control Treg competitive survival and Tfr development to prevent autoimmune diseases. Cell Rep. 2019;27:3629–45.

    Article  CAS  Google Scholar 

  27. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7.

    Article  CAS  Google Scholar 

  28. Rubtsov YP, Niec RE, Josefowicz S, Li L, Darce J, Mathis D, et al. Stability of the regulatory T cell lineage in vivo. Science. 2010;329:1667–71.

    Article  CAS  Google Scholar 

  29. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211–8.

    CAS  PubMed  Google Scholar 

  30. Saravia J, Zeng H, Dhungana Y, Bastardo Blanco D, Nguyen TM, Chapman NM, et al. Homeostasis and transitional activation of regulatory T cells require c-Myc. Sci Adv. 2020;6:eaaw6443.

    Article  CAS  Google Scholar 

  31. Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36:483–97.

    Article  CAS  Google Scholar 

  32. Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3:149–60.

    Article  CAS  Google Scholar 

  33. Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116:9999–10008.

    Article  CAS  Google Scholar 

  34. Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, et al. alpha-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by alpha-TGFbeta antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer. 2019;7:62.

    Article  CAS  Google Scholar 

  35. Tan CL, Kuchroo JR, Sage PT, Liang D, Francisco LM, Buck J, et al. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021;218:e20182232.

    Article  CAS  Google Scholar 

  36. van der Veeken J, Gonzalez AJ, Cho H, Arvey A, Hemmers S, Leslie CS, et al. Memory of inflammation in regulatory T cells. Cell. 2016;166:977–90.

    Article  Google Scholar 

Download references

Acknowledgements

We thank all members of the Xiao and Liu labs (Xiamen University), Xiao Lei Chen (Xiamen University), Chia-Hao Lin and Li-Fan Lu (UCSD) for discussion and technical assistance. We thank Lixin Hong, Xiaohong Ma, Xiufeng Sun at the Xiamen University Flow Cytometry Core and Suqin Wu in the XMU Laboratory Animal Center for technical assistance. This study was supported by the National Natural Science Foundation of China (31770953, 81830047, 81961138008 to CX, 32070877 to W-HL, and 31570883 to NX), 1000 Young Talents Program of China (NX), and the Fundamental Research Funds for the Central Universities of China-Xiamen University (20720170064 to CX). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Author notes

  1. Zhe Huang & Changchun Xiao

    Present address: Sanofi Institute for Biomedical Research, Suzhou, 215123, Jiangsu, China

  2. These authors contributed equally: Chao Yang, Yun Liu, Yudi Hu.

Authors and Affiliations

  1. State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, 361102, Fujian, China

    Chao Yang, Yun Liu, Jun Xie, Yazhen Hong, Nengming Xiao, Wen-Hsien Liu & Changchun Xiao

  2. Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361102, Fujian, China

    Yudi Hu & Qiyuan Li

  3. Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences and Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen, 518005, Guangdong, China

    Liang Fang, Huanhuan Cui & Wei Chen

  4. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA

    Zhe Huang & Changchun Xiao

Authors
  1. Chao Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yudi Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liang Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhe Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huanhuan Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yazhen Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nengming Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qiyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wen-Hsien Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Changchun Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CY, YL and CX conceived the study. CY and YL performed most mouse, cell and molecular biology experiments. CY, YL and LF performed the single-cell sequencing experiment. YH analyzed the single-cell sequencing and RNA sequencing data. HC and JX performed some molecular experiments. YH, WC, NX, QL, W-HL, and CX cosupervised the project. CY, YL, ZH, W-HL, and CX wrote the manuscript with input from all authors.

Corresponding authors

Correspondence to Chao Yang, Qiyuan Li, Wen-Hsien Liu or Changchun Xiao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, C., Liu, Y., Hu, Y. et al. Myc inhibition tips the immune balance to promote antitumor immunity. Cell Mol Immunol 19, 1030–1041 (2022). https://doi.org/10.1038/s41423-022-00898-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-022-00898-7

Keywords

Search

Advanced search

Quick links